AU2577799A - 45 human secreted proteins - Google Patents

45 human secreted proteins

Info

Publication number
AU2577799A
AU2577799A AU25777/99A AU2577799A AU2577799A AU 2577799 A AU2577799 A AU 2577799A AU 25777/99 A AU25777/99 A AU 25777/99A AU 2577799 A AU2577799 A AU 2577799A AU 2577799 A AU2577799 A AU 2577799A
Authority
AU
Australia
Prior art keywords
secreted proteins
human secreted
human
proteins
secreted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU25777/99A
Other languages
English (en)
Inventor
Hla Kyaw
David W. Lafleur
Paul A Moore
Craig A Rosen
Steven M. Ruben
Yanggu Shi
Ying-Fei Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of AU2577799A publication Critical patent/AU2577799A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
AU25777/99A 1998-02-09 1999-02-04 45 human secreted proteins Abandoned AU2577799A (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US7403798P 1998-02-09 1998-02-09
US7434198P 1998-02-09 1998-02-09
US7414198P 1998-02-09 1998-02-09
US7415798P 1998-02-09 1998-02-09
US7411898P 1998-02-09 1998-02-09
US60074141 1998-02-09
US60074037 1998-02-09
US60074118 1998-02-09
US60074341 1998-02-09
US60074157 1998-02-09
PCT/US1999/002293 WO1999040100A1 (en) 1998-02-09 1999-02-04 45 human secreted proteins

Publications (1)

Publication Number Publication Date
AU2577799A true AU2577799A (en) 1999-08-23

Family

ID=27535993

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25777/99A Abandoned AU2577799A (en) 1998-02-09 1999-02-04 45 human secreted proteins

Country Status (6)

Country Link
US (8) US6569992B1 (enExample)
EP (1) EP1053245A4 (enExample)
JP (1) JP2002502589A (enExample)
AU (1) AU2577799A (enExample)
CA (1) CA2320625A1 (enExample)
WO (1) WO1999040100A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132252A1 (en) * 1997-06-16 2002-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
AU2577799A (en) 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
ATE402954T1 (de) * 1998-03-20 2008-08-15 Genentech Inc Menschliches a33-antigen-ähnliches protein und dafür kodierende nukleinsäure
WO1999055733A1 (en) * 1998-04-24 1999-11-04 Smithkline Beecham Corporation Cloning of a novel 7tm receptor axor-2
US7071304B2 (en) * 1998-09-01 2006-07-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000032774A1 (en) * 1998-11-25 2000-06-08 Millennium Pharmaceuticals, Inc. 12216 receptor, a g-protein coupled receptor
US7026449B2 (en) * 1999-01-05 2006-04-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
JP2003506042A (ja) 1999-08-03 2003-02-18 ミレニアム ファーマシューティカルズ インク． セクレチン様ファミリーの新規ｇｐｃｒ様分子１５５７１及びその使用
AU1578801A (en) * 1999-11-05 2001-06-06 Human Genome Sciences, Inc. 29 human secreted proteins
AU1472801A (en) * 1999-11-12 2001-06-06 Human Genome Sciences, Inc. 24 human secreted proteins
CA2390438A1 (en) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 19 human secreted proteins
US20020082405A1 (en) * 2000-03-06 2002-06-27 Gregory Donoho Novel human transporter proteins and polynucleotides encoding the same
JP2004528006A (ja) * 2000-09-29 2004-09-16 インサイト・ゲノミックス・インコーポレイテッド 分泌タンパク質
WO2002092804A1 (en) * 2001-05-15 2002-11-21 Biovitrum Ab Metalloprotease m8 polynucleotides and polypeptides and screening methods
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
EP1539218A4 (en) 2002-06-20 2007-08-22 Univ California COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
WO2007001459A2 (en) 2004-11-15 2007-01-04 Washington University Compositions and methods for modulating lymphocyte activity
US7153950B2 (en) 2002-10-25 2006-12-26 Genentech, Inc. Nucleic acids encoding an immune related polypeptide
US20040248257A1 (en) * 2003-04-30 2004-12-09 The Scripps Research Institute SPEX compositions and methods of use
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
DK2500030T4 (en) 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
WO2007120638A2 (en) * 2006-04-12 2007-10-25 President And Fellows Of Harvard College Methods and compositions for modulating glycosylation
US7776573B2 (en) 2006-06-01 2010-08-17 Genentech, Inc. Crystal structure of CRIg and C3b:CRIg complex
CN106084055A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
US8524444B2 (en) 2007-06-15 2013-09-03 President And Fellows Of Harvard College Methods and compositions for detections and modulating O-glycosylation
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
HRP20161580T1 (hr) 2008-05-06 2016-12-30 Genentech, Inc. CRIg-VARIJANTE S RAZVIJENIM AFINITETOM
JP2012528858A (ja) 2009-06-01 2012-11-15 プレジデント アンド フェロウズ オブ ハーバード カレッジ Ｏ−ＧｌｃＮＡｃ転移酵素阻害剤およびその使用
US8303952B2 (en) 2009-06-08 2012-11-06 Washington University Methods for inducing in vivo tolerance
JP2015504413A (ja) 2011-10-28 2015-02-12 パトリス リミテッド Ｐａｔ−ｌｍ１エピトープおよびそれを使用するための方法
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
CN110036029A (zh) 2016-11-17 2019-07-19 瑞泽恩制药公司 用抗angptl8抗体处理肥胖的方法
WO2019126194A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
WO2020047251A1 (en) 2018-08-29 2020-03-05 President And Fellows Of Harvard College O-glcnac transferase inhibitors and uses thereof
CN112980883B (zh) * 2021-03-03 2022-04-12 广州达博生物制品有限公司 一种人γ-干扰素病毒载体及其应用
CN117441021A (zh) * 2021-06-11 2024-01-23 孟山都技术有限公司 用于改变蛋白积聚的方法和组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001225A (en) * 1986-12-08 1991-03-19 Georgetown University Monoclonal antibodies to a pan-malarial antigen
US5118617A (en) * 1989-05-19 1992-06-02 Applied Research Systems Ars Holding N.V. Saf polypeptide, gene coding therefor, saf promoter and expression methods for expressing foreign dna sequences in streptomyces
JP2879303B2 (ja) * 1993-01-14 1999-04-05 佑 本庶 ｃＤＮＡライブラリーの作製方法、および新規なポリペプチドとそれをコードするＤＮＡ
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
US5744355A (en) * 1994-10-18 1998-04-28 Mayo Foundation For Medical Education And Research cDNA cloning and expression of human liver estrogen sulfotransferase
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US20060223088A1 (en) * 1997-03-07 2006-10-05 Rosen Craig A Human secreted proteins
AU6956798A (en) * 1997-04-10 1998-10-30 Genetics Institute Inc. Secreted expressed sequence tags (sests)
US20030073129A1 (en) * 1998-09-01 2003-04-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6312922B1 (en) 1998-02-09 2001-11-06 Genset Complementary DNAs
AU2577799A (en) 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
CA2331386A1 (en) 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
NZ510464A (en) 1998-09-01 2004-05-28 Genentech Inc Further pro polypeptides and sequences thereof
PT1623990E (pt) 1999-03-08 2008-03-18 Genentech Inc Composições e métodos para o tratamento de tumores
EP1130094A3 (en) 1999-07-08 2001-11-21 Helix Research Institute Primers for synthesizing full length cDNA clones and their use
CA2402563A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001077290A2 (en) 2000-04-06 2001-10-18 Genetics Institute, Llc. Polynucleotides encoding novel secreted proteins
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US8067152B2 (en) * 2006-02-27 2011-11-29 The Fred Hutchinson Cancer Research Center Liver cancer biomarkers

Also Published As

Publication number Publication date
EP1053245A4 (en) 2002-04-17
US20060281095A1 (en) 2006-12-14
WO1999040100A1 (en) 1999-08-12
US20050079537A1 (en) 2005-04-14
US20050153335A1 (en) 2005-07-14
US20050009085A1 (en) 2005-01-13
US20030096982A1 (en) 2003-05-22
US6569992B1 (en) 2003-05-27
CA2320625A1 (en) 1999-08-12
US6924356B2 (en) 2005-08-02
US20090088555A1 (en) 2009-04-02
US20070154918A1 (en) 2007-07-05
EP1053245A1 (en) 2000-11-22
JP2002502589A (ja) 2002-01-29

Similar Documents

Publication Publication Date Title
AU4682999A (en) 94 human secreted proteins
AU5134799A (en) 98 human secreted proteins
AU5583799A (en) 49 human secreted proteins
AU6552198A (en) 28 human secreted proteins
AU2306499A (en) 110 human secreted proteins
AU1473501A (en) 21 human secreted proteins
AU3124000A (en) 47 human secreted proteins
AU6952998A (en) 20 human secreted proteins
AU2471899A (en) 67 human secreted proteins
AU2451199A (en) 36 human secreted proteins
AU8066998A (en) 86 human secreted proteins
AU9130498A (en) 50 human secreted proteins
AU5212299A (en) 71 human secreted proteins
AU5928899A (en) 31 human secreted proteins
AU1231400A (en) 12 human secreted proteins
AU5591200A (en) 49 human secreted proteins
AU8404598A (en) 64 human secreted proteins
AU3769700A (en) 45 human secreted proteins
AU3006799A (en) 31 human secreted proteins
AU6745700A (en) 49 human secreted proteins
AU1273499A (en) 148 human secreted proteins
AU1916101A (en) 19 human secreted proteins
AU8921598A (en) 29 human secreted proteins
AU5458300A (en) 26 human secreted proteins
AU3208700A (en) 33 human secreted proteins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase